DeLLphi-305 is a Phase 3 clinical trial that is testing an investigational drug called tarlatamab. This clinical trial aims to see how safe and effective tarlatamab is at treating patients with small-cell lung cancer (SCLC). Participants will receive either tarlatamab in combination with durvalumab (Imfinzi®) or durvalumab alone.
Talk to an Amgen Medical Information Healthcare Professional to see if you qualify.
Patients who are 18 years or older
Diagnosed with small-cell lung cancer (SCLC) by tumor sample under a microscope
Small-cell lung cancer (SCLC) is in both lungs or has spread to other areas
Received (or plan to receive) a platinum-containing chemotherapy with durvalumab for initial treatment
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
Step 1: Screening
At your first visit(s), you will:
*This may not be needed in all cases. Your doctor will let you know if this is not needed.
If you meet the requirements and decide to join this clinical trial, you will move on to Step 2.
Step 2: Treatment
Approximately 550 participants will be randomly assigned to receive either tarlatamab (investigational drug) in combination with durvalumab (Imfinzi®) or durvalumab alone.
The tarlatamab group will:
The durvalumab group will:
Step 3: End of treatment
You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. The treatment you receive in this trial or your participation in this clinical trial may end if:
The clinical trial team will schedule a follow-up visit with you approximately 12 weeks after your last trial treatment.
Step 4: Long term follow-up (up to 3 years)
The clinical trial team may follow-up with you by phone or ask you to visit the clinic approximately once every 3 months.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.